Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 ...

The executive order aims to lower prescription prices, but targets the mechanism for negotiating small molecule drug costs.

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

When the mechanisms that replicate or repair mitochondrial DNA (mtDNA) fail, it can cause a wide range of syndromes for which ...

The Inflation Reduction Act was intended to lower prescription drug costs, but an unintended consequence is threatening the future of medicines.

In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average target of $3.83, a high estimate of $6.00, and a low estimate of $1.00. This ...

Telomir Pharmaceuticals, Inc.’s TELO share price has dipped by 17.60%, which has investors questioning if this is right time to buy.

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 25.32%, which has investors questioning if this is right time to buy.